Transcriptional landscape of PDAC shows distinct cell populations
Peer-Reviewed Publication
Updates every hour. Last Updated: 4-May-2025 11:09 ET (4-May-2025 15:09 GMT/UTC)
Pancreatic cancer is one of the leading causes of cancer-related mortality, with pancreatic ductal adenocarcinoma (PDAC) accounting for 90% of all cases. As most PDAC cases are diagnosed at advanced stages, surgical interventions are ineffective, and consequently, lymph node metastasis manifests in 70% of PDAC patients. Moreover, since the number of genetic mutations giving rise to PDAC are low, there are fewer available targeted therapeutic modalities. Analysis of gene expression at the single-cell level may help understand the tumor dynamics of PDAC.
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide. Despite the success of immune checkpoint blockade therapies in various solid tumors, immunotherapy for CRC remains a challenge. Hence, there is a critical need to understand the complex tumor microenvironment (TME) of CRC and identify potential targets to develop new immunotherapies.
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
This tool is a type of molecular residual disease (MRD)detector, which is used after patients have completed their primary treatment in order to monitor their cancer status. Researchers say it could inform clinical intervention, including whether to restart or intensify treatment.
Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality.
Physical fitness and increasing muscle strength could reduce the mortality rate for cancer patients by between 31% to 46%, new research from Edith Cowan University (ECU) has found.
Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple organs, conventional treatments like surgery, radiation, and chemotherapy become less effective. Scientists at Shinshu University School of Medicine have developed a synthetic mRNA that, when injected, revitalizes the immune system to recognize and attack metastasizing cancer cells. This breakthrough could lead to new therapies to improve survival rates for cancer patients.
Led by Singapore, a 12-year, international, multi-centre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal cancer in over 1,500 patients has been completed and published in The Lancet Gastroenterology and Hepatology.
This is the world’s first chemoprevention trial repurposing aspirin to reduce colorectal cancer recurrence following standard surgery and adjuvant chemotherapy treatment.
Results define the role and benefit of the easily accessible, low-cost drug, aspirin, in reducing colorectal cancer recurrence in a selected colorectal cancer patient population.
Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolism ‘switch’ to help it spread, revealing a potential new treatment strategy for this highly aggressive disease.